Lexeo Therapeutics (LXEO) Competitors $7.93 +0.03 (+0.38%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LXEO vs. SAVA, PRAX, DAWN, GYRE, AVDL, ANIP, AUTL, CALT, BCAX, and COLLShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Cassava Sciences (SAVA), Praxis Precision Medicines (PRAX), Day One Biopharmaceuticals (DAWN), Gyre Therapeutics (GYRE), Avadel Pharmaceuticals (AVDL), ANI Pharmaceuticals (ANIP), Autolus Therapeutics (AUTL), Calliditas Therapeutics AB (publ) (CALT), Bicara Therapeutics (BCAX), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. Cassava Sciences Praxis Precision Medicines Day One Biopharmaceuticals Gyre Therapeutics Avadel Pharmaceuticals ANI Pharmaceuticals Autolus Therapeutics Calliditas Therapeutics AB (publ) Bicara Therapeutics Collegium Pharmaceutical Lexeo Therapeutics (NASDAQ:LXEO) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation. Is LXEO or SAVA more profitable? Cassava Sciences' return on equity of -88.23% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -103.43% -51.50% Cassava Sciences N/A -88.23%-68.31% Do insiders and institutionals hold more shares of LXEO or SAVA? 60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer LXEO or SAVA? Cassava Sciences received 81 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 65.54% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformLexeo TherapeuticsOutperform Votes16100.00% Underperform VotesNo VotesCassava SciencesOutperform Votes9765.54% Underperform Votes5134.46% Which has better earnings and valuation, LXEO or SAVA? Lexeo Therapeutics has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo Therapeutics$650K403.34-$66.39M-$14.63-0.54Cassava SciencesN/AN/A-$97.22M-$1.41-18.59 Does the media prefer LXEO or SAVA? In the previous week, Lexeo Therapeutics had 4 more articles in the media than Cassava Sciences. MarketBeat recorded 9 mentions for Lexeo Therapeutics and 5 mentions for Cassava Sciences. Lexeo Therapeutics' average media sentiment score of 0.72 beat Cassava Sciences' score of 0.11 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate LXEO or SAVA? Lexeo Therapeutics presently has a consensus price target of $22.14, suggesting a potential upside of 179.23%. Cassava Sciences has a consensus price target of $111.50, suggesting a potential upside of 325.41%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Lexeo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Cassava Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryLexeo Therapeutics beats Cassava Sciences on 11 of the 16 factors compared between the two stocks. Ad DarwinUnlock the Secret to Earning Consistent Income from Stocks Under $30!Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!👉 Yes, I Want the Free Report! 👈 Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$261.18M$3.15B$5.54B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-0.5411.73114.8115.14Price / Sales403.34397.851,495.55100.10Price / CashN/A148.6639.6734.08Price / Book1.864.024.665.02Net Income-$66.39M-$42.25M$119.06M$225.46M7 Day Performance-16.53%8.04%0.80%0.37%1 Month Performance-9.06%8.69%5.65%3.57%1 Year PerformanceN/A32.09%36.75%29.43% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics3.195 of 5 stars$7.93+0.4%$22.14+179.2%N/A$261.18M$650,000.00-0.5458Analyst ForecastNews CoverageSAVACassava Sciences3.7398 of 5 stars$26.73+0.7%$111.50+317.1%+70.3%$1.28BN/A-18.9630Upcoming EarningsNews CoveragePRAXPraxis Precision Medicines2.7039 of 5 stars$71.73+0.3%$143.44+100.0%+375.4%$1.27B$2.45M-7.00110Upcoming EarningsAnalyst ForecastPositive NewsDAWNDay One Biopharmaceuticals1.844 of 5 stars$14.47-0.9%$35.71+146.8%+23.7%$1.26B$8.19M-7.4260Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGYREGyre TherapeuticsN/A$14.39+1.3%N/AN/A$1.23B$111.59M0.0040AVDLAvadel Pharmaceuticals2.9274 of 5 stars$12.80-0.6%$24.57+92.0%+45.8%$1.23B$95.15M-10.94154Analyst ForecastOptions VolumeNews CoverageANIPANI Pharmaceuticals4.8547 of 5 stars$57.97-0.6%$77.33+33.4%-5.6%$1.22B$538.95M49.55642Short Interest ↓Gap UpAUTLAutolus Therapeutics3.1342 of 5 stars$4.55+2.5%$8.70+91.2%+18.6%$1.21B$10.50M-3.92330Short Interest ↓CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180BCAXBicara Therapeutics1.682 of 5 stars$22.35-0.7%$41.00+83.4%N/A$1.16BN/A0.0032Positive NewsCOLLCollegium Pharmaceutical4.0303 of 5 stars$35.13+1.2%$42.60+21.3%+53.5%$1.15B$576.65M13.62210Upcoming Earnings Related Companies and Tools Related Companies Cassava Sciences Competitors Praxis Precision Medicines Competitors Day One Biopharmaceuticals Competitors Gyre Therapeutics Competitors Avadel Pharmaceuticals Competitors ANI Pharmaceuticals Competitors Autolus Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Bicara Therapeutics Competitors Collegium Pharmaceutical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LXEO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
